Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During
the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as
monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX
FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of
the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2.
During the Part 2 dose expansion portion of the trial, patients will either receive
NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous
(DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab.
This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in
combination with daratumumab or rituximab.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04136756.
NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation,
proliferation and promote their anti-tumor effects.
This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety
follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in
combination with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any
investigational treatment(s) or marketed product(s), intended to be administered to a
study patient according to the study enrollment.
Part 1 will enroll relapsed/refractory multiple myeloma (MM) and Non-Hodgkin's Lymphoma
(NHL) patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a
chimeric antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who
previously received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone
and/or in combination with daratumumab, and Cohort C will enroll indolent Non-Hodgkin's
Lymphoma (iNHL) patients who previously received rituximab and other therapies to receive
NKTR-255 alone and/or in combination with rituximab.
